132 related articles for article (PubMed ID: 38652112)
1. Characterizing the Nonlinear Pharmacokinetics and Pharmacodynamics of BI 187004, an 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Humans by a Target-Mediated Drug Disposition Model.
Yuan X; An G
J Clin Pharmacol; 2024 Apr; ():. PubMed ID: 38652112
[TBL] [Abstract][Full Text] [Related]
2. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
3. A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults.
Wu N; Katz DA; An G
J Clin Pharmacol; 2021 Nov; 61(11):1442-1453. PubMed ID: 34110620
[TBL] [Abstract][Full Text] [Related]
4. Safety, pharmacokinetics and pharmacodynamics of BI 135585, a selective 11β-hydroxysteroid dehydrogenase-1 (HSD1) inhibitor in humans: liver and adipose tissue 11β-HSD1 inhibition after acute and multiple administrations over 2 weeks.
Freude S; Heise T; Woerle HJ; Jungnik A; Rauch T; Hamilton B; Schölch C; Huang F; Graefe-Mody U
Diabetes Obes Metab; 2016 May; 18(5):483-90. PubMed ID: 26799632
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, pharmacokinetics and pharmacodynamics of single oral doses of BI 187004, an inhibitor of 11beta-hydroxysteroid dehydrogenase-1, in healthy male volunteers with overweight or obesity.
Bianzano S; Heise T; Jungnik A; Schepers C; Schölch C; Gräfe-Mody U
Clin Diabetes Endocrinol; 2021 Aug; 7(1):16. PubMed ID: 34391480
[TBL] [Abstract][Full Text] [Related]
6. Importance of Target-Mediated Drug Disposition (TMDD) of Small-Molecule Compounds and Its Impact on Drug Development-Example of the Class Effect of HSD-1 Inhibitors.
An G; Katz DA
J Clin Pharmacol; 2023 May; 63(5):526-538. PubMed ID: 36479709
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetic/pharmacodynamic model of subcutaneous adipose 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) activity after oral administration of AMG 221, a selective 11β-HSD1 inhibitor.
Gibbs JP; Emery MG; McCaffery I; Smith B; Gibbs MA; Akrami A; Rossi J; Paweletz K; Gastonguay MR; Bautista E; Wang M; Perfetti R; Daniels O
J Clin Pharmacol; 2011 Jun; 51(6):830-41. PubMed ID: 20663992
[TBL] [Abstract][Full Text] [Related]
8. A Pharmacometrics Model to Characterize a New Type of Target-Mediated Drug Disposition (TMDD) - Nonlinear Pharmacokinetics of Small-Molecule PF-07059013 Mediated By Its High-capacity Pharmacological Target Hemoglobin With Positive Cooperative Binding.
Xu M; An G
AAPS J; 2023 Apr; 25(3):41. PubMed ID: 37055588
[TBL] [Abstract][Full Text] [Related]
9. Selective Inhibition of 11beta-Hydroxysteroiddehydrogenase-1 with BI 187004 in Patients with Type 2 Diabetes and Overweight or Obesity: Safety, Pharmacokinetics, and Pharmacodynamics After Multiple Dosing Over 14 Days.
Bianzano S; Schepers C; Wolff M; Heise T; Plum-Moerschel L
Exp Clin Endocrinol Diabetes; 2022 Dec; 130(12):773-782. PubMed ID: 36343645
[TBL] [Abstract][Full Text] [Related]
10. Concept of Pharmacologic Target-Mediated Drug Disposition in Large-Molecule and Small-Molecule Compounds.
An G
J Clin Pharmacol; 2020 Feb; 60(2):149-163. PubMed ID: 31793004
[TBL] [Abstract][Full Text] [Related]
11. Selection and early clinical evaluation of the brain-penetrant 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitor UE2343 (Xanamem™).
Webster SP; McBride A; Binnie M; Sooy K; Seckl JR; Andrew R; Pallin TD; Hunt HJ; Perrior TR; Ruffles VS; Ketelbey JW; Boyd A; Walker BR
Br J Pharmacol; 2017 Mar; 174(5):396-408. PubMed ID: 28012176
[TBL] [Abstract][Full Text] [Related]
12. Incorporating Pharmacological Target-Mediated Drug Disposition (TMDD) in a Whole-Body Physiologically Based Pharmacokinetic (PBPK) Model of Linagliptin in Rat and Scale-up to Human.
Wu N; An G
AAPS J; 2020 Sep; 22(6):125. PubMed ID: 32996028
[TBL] [Abstract][Full Text] [Related]
13. Continuous inhibition of 11β-hydroxysteroid dehydrogenase type I in adipose tissue leads to tachyphylaxis in humans and rats but not in mice.
Morentin Gutierrez P; Gyte A; deSchoolmeester J; Ceuppens P; Swales J; Stacey C; Eriksson JW; Sjöstrand M; Nilsson C; Leighton B
Br J Pharmacol; 2015 Oct; 172(20):4806-16. PubMed ID: 26218540
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability, pharmacodynamics and pharmacokinetics following once-daily doses of BI 187004, an inhibitor of 11 beta-hydroxysteroid dehydrogenase-1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.
Bianzano S; Nordaby M; Plum-Mörschel L; Peil B; Heise T
Diabetes Obes Metab; 2023 Mar; 25(3):832-843. PubMed ID: 36478142
[TBL] [Abstract][Full Text] [Related]
15. Quantification of 11β-hydroxysteroid dehydrogenase 1 kinetics and pharmacodynamic effects of inhibitors in brain using mass spectrometry imaging and stable-isotope tracers in mice.
Cobice DF; Livingstone DEW; McBride A; MacKay CL; Walker BR; Webster SP; Andrew R
Biochem Pharmacol; 2018 Feb; 148():88-99. PubMed ID: 29248595
[TBL] [Abstract][Full Text] [Related]
16. First in human randomised trial of J2H-1702: A novel 11β-hydroxysteroid dehydrogenase type 1 inhibitor for non-alcoholic steatohepatitis treatment.
Kim Y; Lee SR; Lee SW
Aliment Pharmacol Ther; 2023 Dec; 58(11-12):1132-1142. PubMed ID: 37743843
[TBL] [Abstract][Full Text] [Related]
17. 11β-Hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors still improve metabolic phenotype in male 11β-HSD1 knockout mice suggesting off-target mechanisms.
Harno E; Cottrell EC; Yu A; DeSchoolmeester J; Gutierrez PM; Denn M; Swales JG; Goldberg FW; Bohlooly-Y M; Andersén H; Wild MJ; Turnbull AV; Leighton B; White A
Endocrinology; 2013 Dec; 154(12):4580-93. PubMed ID: 24169553
[TBL] [Abstract][Full Text] [Related]
18. 11beta-hydroxysteroid dehydrogenase type 1 inhibitors as promising therapeutic drugs for diabetes: status and development.
Ge R; Huang Y; Liang G; Li X
Curr Med Chem; 2010; 17(5):412-22. PubMed ID: 20015040
[TBL] [Abstract][Full Text] [Related]
19. Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects.
Bellaire S; Walzer M; Wang T; Krauwinkel W; Yuan N; Marek GJ
Clin Transl Sci; 2019 May; 12(3):291-301. PubMed ID: 30740895
[TBL] [Abstract][Full Text] [Related]
20. Increased whole-body and sustained liver cortisol regeneration by 11beta-hydroxysteroid dehydrogenase type 1 in obese men with type 2 diabetes provides a target for enzyme inhibition.
Stimson RH; Andrew R; McAvoy NC; Tripathi D; Hayes PC; Walker BR
Diabetes; 2011 Mar; 60(3):720-5. PubMed ID: 21266326
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
